Treatment of Complicated Staphylococcus aureus Bacteremia
From Healthy Dialogue by JAMA Network
August 13, 2025 · 12 min
About this episode
The episode discusses the potential of Dalbavancin as a treatment for complicated Staphylococcus aureus bacteremia.
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia
People in this episode
Host: Preeti Malani, MD, MSJ
Guest: Thomas L. Holland, MD, MSc
Topics covered
- Staphylococcus aureus bacteremia
- Dalbavancin
- IV lipoglycopeptide
- DOTS randomized clinical trial
- antibiotic treatment
Keywords
- Dalbavancin
- Staphylococcus aureus
- bacteremia
- IV treatment
- clinical trial
- antibiotics
- long-term access
Mentioned in this episode
Organizations: Duke University School of Medicine, JAMA Network
More episodes of Healthy Dialogue
- Private Equity's Growing Presence in Health Care: Promise or Peril? · June 3, 2026 · 40 min
- A New Era in Dementia: Advances in Diagnostic Blood Tests, Novel Drugs, and the Power of Lifestyle Changes · May 20, 2026 · 46 min
- AI Scribes Are Here, but Is Health Care Ready? · May 6, 2026 · 41 min
- Rethinking the Autism "Epidemic": What's Driving the Rise in Diagnosis · April 22, 2026 · 36 min
- Introducing Healthy Dialogue · April 17, 2026 · 2 min
- From the JAMA Network: JAMA Research of the Year With Editor in Chief Kirsten Bibbins-Domingo · December 26, 2025 · 16 min
Explore listener stats, chart rankings, contacts and more on the Healthy Dialogue podcast page.